Hims & Hers Health, Inc. (NYSE:HIMS) Receives $45.50 Consensus Price Target from Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS) has earned an average rating of “Hold” from the seventeen ratings firms that are currently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $45.50.

HIMS has been the subject of several recent research reports. Leerink Partnrs upgraded shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday. Barclays assumed coverage on Hims & Hers Health in a report on Monday, December 8th. They issued an “overweight” rating and a $48.00 price target on the stock. Finally, BTIG Research restated a “buy” rating and set a $85.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, November 4th.

Hims & Hers Health Trading Down 1.8%

Shares of NYSE HIMS opened at $32.45 on Friday. Hims & Hers Health has a twelve month low of $23.97 and a twelve month high of $72.98. The firm has a market cap of $7.39 billion, a PE ratio of 60.09, a price-to-earnings-growth ratio of 6.42 and a beta of 2.37. The business has a fifty day simple moving average of $38.41 and a two-hundred day simple moving average of $47.18. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The firm had revenue of $598.98 million for the quarter, compared to analysts’ expectations of $578.99 million. During the same quarter in the prior year, the business posted $0.32 EPS. The business’s quarterly revenue was up 49.2% on a year-over-year basis. Analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health declared that its Board of Directors has approved a share buyback program on Monday, November 17th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to purchase up to 3% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Irene Becklund sold 8,411 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the completion of the sale, the insider owned 2,126 shares of the company’s stock, valued at $78,045.46. This represents a 79.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Deborah M. Autor sold 7,054 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the completion of the sale, the insider owned 6,175 shares of the company’s stock, valued at approximately $226,684.25. This trade represents a 53.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 131,603 shares of company stock valued at $5,172,422. 13.71% of the stock is currently owned by corporate insiders.

Institutional Trading of Hims & Hers Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. HighTower Advisors LLC purchased a new position in Hims & Hers Health during the 1st quarter worth $482,000. American Century Companies Inc. boosted its holdings in Hims & Hers Health by 31.5% in the first quarter. American Century Companies Inc. now owns 185,065 shares of the company’s stock worth $5,469,000 after acquiring an additional 44,307 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Hims & Hers Health by 15.7% during the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock worth $49,000 after acquiring an additional 227 shares during the last quarter. MetLife Investment Management LLC grew its stake in shares of Hims & Hers Health by 87.9% during the first quarter. MetLife Investment Management LLC now owns 215,753 shares of the company’s stock worth $6,376,000 after acquiring an additional 100,957 shares during the last quarter. Finally, Freedom Investment Management Inc. acquired a new position in shares of Hims & Hers Health during the first quarter valued at about $380,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.